This site is intended for Healthcare Professionals only.

Defect information notice issued for Ibuprofen tablets of Aspar

Date:

Share post:

The Medicines and Health products Regulatory Agency (MHRA) has issued a class four medicines defect information notice for Ibuprofen 200mg and 400mg tablets of Aspar Pharmaceuticals.

The patient information leaflets (PILs) within the ibuprofen packs are missing some information which should be documented in section three and section four of the PIL, Aspar Pharmaceuticals Limited has said.

How to take the tablets (section three)

Current information in the PIL Correct information that should be included in the PIL
Seek medical attention IMMEDIATELY if you accidentally take too many tablets. Seek medical attention IMMEDIATELY if you accidentally take too many tablets. If you have taken more than you should, or if children have taken this medicine by accident always contact a doctor or nearest hospital to get an opinion of the risk and advice on action to be taken. The symptoms can include nausea, stomach pain, vomiting (may be blood-streaked), headache, ringing in the ears, confusion and shaky eye movement. At high doses, drowsiness, chest pain, palpitations, loss of consciousness, convulsions (mainly in children), weakness and dizziness, blood in urine, cold body feeling, and breathing problems have been reported.

 

Possible side effects (section four)

Current information in the PIL Correct information that should be included in the PIL
(No appropriate wording related to DRESS syndrome) A severe skin reaction known as DRESS syndrome can occur. Symptoms of DRESS include: skin rash, fever, swelling of lymph nodes and an increase of eosinophils (a type of white blood cells).

 

Product Description
MDR number of the product is MDR 054-07/20 and ibuprofen is the active pharmaceutical ingredient.

Product Pack Size PL Number
Aspar Ibuprofen 200mg Caplets (GSL) 16 PL 08977/0015

 

Product Pack Size PL Number
Nisa Ibuprofen Tablets BP 200mg (GSL) 16 PL 08977/0016
Lloyds Pharmacy Ibuprofen 200mg Tablets (GSL) 16 PL 08977/0016
Lloyds Pharmacy Ibuprofen200mg Tablets (P) 24, 48, 16 PL 08977/0016
Lifestyle Ibuprofen Tablets BP 200mg (GSL) 16 PL 08977/0016
Ibucalm 200mg Tablets (GSL) 16 PL 08977/0016
Ibucalm 200mg Tablets (P) 24, 48, 16 PL 08977/0016
Careway Ibuprofen 200mg Tablets (GSL) 16 PL 08977/0016
Careway Ibuprofen 200mg Tablets (P) 25, 48 PL 08977/0016
Asda Ibuprofen 200mg Tablets (P) 48 PL 08977/0016

 

Product Pack Size(s) PL Number
Ibucalm 400mg Tablets (P) 24, 48, 96 PL 08977/0017
Asda Ibuprofen 400mg Tablets (P) 48, 96 PL 08977/0017
Careway Ibuprofen 400mg Tablets (P) 24, 48 PL 08977/0017
Lloyds Pharmacy Ibuprofen 400mg Tablets (P) 12, 24, 48, 96 PL 08977/0017

 

Advice for healthcare professionals
Community pharmacists have been adviced that if any of the above products are supplied or dispensed, then they should ensure that patients are aware of the missing information as mentioned above.

It is important that any patients who notice any symptoms following the use of the product should seek immediate medical advice.

The patients who experience side effects from taking any medicines should be encouraged to report a suspected problem or incident via the Yellow Card scheme and seek medical advice accordingly.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Haleon to close Maidenhead manufacturing site affecting 435 jobs

Despite the closure, Haleon will retain its presence in the UK with corporate offices in Weybridge and London Haleon,...

UK pharmacies cut prices for weight-loss drugs Wegovy, Mounjaro amidst escalating competition

Obesity experts raise concern that retail marketing of weight-loss drugs could trivialise their side-effects   British pharmacies and slimming...

MHRA says many online pharmacies are ‘unregulated’,’ illegal’, or ‘fraudulent’

MHRA's latest initiative aims to empower consumers in the fight against online pharmacy frauds The Medicines and Healthcare products...

MHRA outlines strategic approach to AI regulation in healthcare for patient safety

MHRA's strategic principles aim to foster innovation while upholding rigorous standards of patient safety and regulatory integrity In a...